Meningococcal polysaccharide vaccine group C

DB13890ApprovedInvestigationalVaccinesInactivated Meningococcal Vaccine

Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup C. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and... It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.

First approval
Canada, 2000 · United States, 1981 · European Union, 2020
Also known as
Meningococcal group C polysaccharide · Meningococcal group CCRM197 conjugate vaccine · Meningococcal polysaccharide antigen group C · Neisseria meningitidis group C (strain C11) oligosaccharide CRM-197 adipic acid conjugate · Neisseria meningitidis group C capsular polysaccharide antigen
Brand names
  • Menquadfi
  • Menveo
  • Nimenrix

Resolves to

Compound
UNII837RU6905N
Clinical / RWD
RxNorm29503

What you can answer from here — as of April 02, 2025

100Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
61Marketed productsAcross 10 countries and 16 labellers
Sign in

Which other approved drugs treat the same conditions as Meningococcal polysaccharide vaccine group C, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In